


Application No: 10/540,075, filed June 22, 2005
Attorney Docket No.: 421-US-PCT
Amendment Dated November 09, 2007
Reply to Office Action dated September 11, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A 1,2,4-triaminobenzene derivative of formula I:



wherein:

R^1 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, acyl, hydroxy- C_{1-6} -alk(en/yn)yl and hydroxy- C_{3-8} -cycloalk(en)yl;

R^2 and $R^{2'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, aryl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, aryl- C_{1-6} -alk(en/yn)yl, acyl, hydroxy- C_{1-6} -alk(en/yn)yl and hydroxy- C_{3-8} -cycloalk(en)yl;

R^3 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, aryl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, aryl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl, aryl- C_{3-8} -cycloalk(en)yl, $NR^{10}R^{10'}$ - C_{1-6} -alk(en/yn)yl, $NR^{10}R^{10'}$ - C_{3-8} -cycloalk(en)yl and hydroxy- C_{3-8} -cycloalk(en)yl[[.]], wherein:

R^{10} and $R^{10'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl, hydroxy- C_{3-8} -cycloalk(en)yl, hydroxy- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{3-8} -cycloalk(en)yl, halo- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, cyano- C_{3-8} -cycloalk(en)yl and cyano- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, or

R^{10} and $R^{10'}$ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]] that optionally contains 1, 2 or 3 further heteroatoms;

X is CO or SO_2 ;


Z is O or NR^4 , wherein:

R^4 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl and hydroxy- C_{3-8} -cycloalk(en)yl; or

R^3 and R^4 together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]] that optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R^3 and R^4 and the nitrogen atom is optionally substituted with one or more substituents independently selected from C_{1-6} -alk(en/yn)yl, aryl and aryl- C_{1-6} -alk(en/yn)yl;

q is 0 or 1; and

Y represents a heteroaryl of formula II:



II

wherein:

W is S;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

p is 0 or 1; and

each R^5 is independently selected from the group consisting of C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, aryl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, aryl- C_{1-6} -alk(en/yn)yl, acyl, halogen, halo- C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, $-CO-NR^6R^6'$, cyano, nitro, $-NR^7R^7'$, $-S-R^8$, $-SO_2R^8$, and SO_2OR^8 [[;]], wherein:

R^6 and $R^{6'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl and aryl;

R^7 and $R^{7'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, aryl and acyl; and

Application No: 10/540,075, filed June 22, 2005

Attorney Docket No.: 421-US-PCT

Amendment Dated November 09, 2007

Reply to Office Action dated September 11, 2007

R^8 is selected from the group consisting of C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, aryl and $-NR^9R^{9'}$ [[;]], [[and]] wherein:

R^9 and $R^{9'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or a pharmaceutically acceptable salt[[salts]] thereof.

Claim 2. (previously presented) The compound according to claim 1 wherein R^1 is selected from the group consisting of hydrogen and C_{1-6} -alk(en/yn)yl.

Claim 3. (previously presented) The compound according to claim 1 wherein at least one of the substituents R^2 and $R^{2'}$ is a hydrogen atom.

Claim 4. (previously presented) The compound according to claim 1 wherein both R^2 and $R^{2'}$ are hydrogen atoms.

Claim 5. (previously presented) The compound according to claim 1 wherein X is CO.

Claim 6. (previously presented) The compound according to claim 1 wherein q is 0.

Claim 7. (previously presented) The compound according to claim 1 wherein q is 1 and Z is an oxygen atom.

Claim 8. (previously presented) The compound according to claim 1 wherein R^3 is selected from the group consisting of C_{1-6} -alk(en/yn)yl and aryl- C_{1-6} -alk(en/yn)yl.

Claim 9. (previously presented) The compound according to claim 8 wherein R^3 is C_{1-6} -alk(en/yn)yl.

Claim 10. (previously presented) The compound according to claim 8 wherein R^3 is aryl- C_{1-6} -alk(en/yn)yl.

Claim 11. (canceled)


Application No: 10/540,075, filed June 22, 2005
Attorney Docket No.: 421-US-PCT
Amendment Dated November 09, 2007
Reply to Office Action dated September 11, 2007

Claim 12. (previously presented) The compound according to claim 1 wherein W is a sulfur atom.

Claim 13. (canceled)

Claim 14. (canceled)


Claim 15. (currently amended) The compound according to claim 1 wherein Y is of formula IIb:



IIb

wherein W, m, n, p and R⁵ are as defined [[above]]in claim 1.

Claim 16. (currently amended) The compound according to claim 1 wherein Y is of formula IIc:



IIc

wherein W, m, n, p and R⁵ are as defined [[above]]in claim 1.

Claim 17. (previously presented) The compound according to claim 1 wherein each R⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, aryl, halogen, C₁₋₆-alk(en/yn)yloxy, -NR⁷R⁷, and -SO₂R⁸.

Claim 18. (currently amended) A compound selected from the group consisting of:

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

Application No: 10/540,075, filed June 22, 2005

Attorney Docket No.: 421-US-PCT

Amendment Dated November 09, 2007

Reply to Office Action dated September 11, 2007

{2-Amino-4-[(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-2-(4-fluoro-phenyl)-acetamide; and

N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-3,3-dimethyl-butyramide;

or a pharmaceutically acceptable salt thereof.

Claim 19. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents.

Claims 20-25. (canceled)

Claim 26. (currently amended) A method of treating a disorder of the central nervous system in a subject, wherein the disorder of the central nervous system is selected from the group consisting of [[a]] seizure-disorder, [[a]] neuropathic pain-disorder, [[a]] migraine pain disorder, and [[an]] anxiety-disorder, a neurogenerative disorder and a neuronal hyperexcitiation state comprising administering a therapeutically effective amount of the compound of claim 1 to the subject.

Claim 27. (currently amended) The method of claim 26, wherein the seizure-disorder is a convulsion, an epilepsy or a status epilepticus.

*Application No: 10/540,075, filed June 22, 2005
Attorney Docket No.: 421-US-PCT
Amendment Dated November 09, 2007
Reply to Office Action dated September 11, 2007*

Claim 28. (currently amended) The method of claim 26, wherein the neuropathic pain-disorder is allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy or neuropathic pain related to migraine.

Claim 29. (currently amended) The method of claim 26, wherein the anxiety-disorder is anxiety, a generalized anxiety-disorder, panic anxiety, an obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, an acute stress reaction, an adjustment disorder, a hypochondriacal disorder, a separation anxiety disorder, agoraphobia, a specific phobia, an anxiety disorder due to a general medical condition or a substance-induced anxiety disorder.

Claims 30-32. (canceled).